Crystalline ppar-delta agonist
US-2024002356-A1 · Jan 4, 2024 · US
US9353073B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9353073-B2 |
| Application number | US-201414767350-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 20, 2014 |
| Priority date | Feb 22, 2013 |
| Publication date | May 31, 2016 |
| Grant date | May 31, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A process for the manufacture of vortioxetine is provided in which a compound of formula I, formula I is reacted with optionally substituted piperazine and 2,4-dimethylthiophenol(ate) followed by de-cmplexation.
Opening claim text (preview).
The invention claimed is: 1. A process for the manufacture of vortioxetine or pharmaceutically acceptable salts thereof, which process comprises reacting a compound of formula I wherein each Hal independently represents fluoro or chloro; R′ represents H or R′ represents one or two moieties independently selected from CHO, COOH, COOR′″ or COONR′″ 2 , or R′ represents one to five moieties independently selected from C 1-6 -alkyl; R′″ independently represents H or C 1-6 -alkyl; and X − represents a non-coordinating and non-nucleophilic anion, with a piperazine of formula II wherein R represents H, and with a compound of formula III wherein R″ represents H or a cation, and an optional base in a solvent to obtain a compound of formula IV followed by a de-complexation step in which the optionally substituted cyclopentadienyliron is de-complexed to obtain 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine (vortioxetine). 2. The process according to claim 1 , wherein Hal represents chloro. 3. The process according to claim 1 , wherein R′ represents hydrogen. 4. The process according to claim 1 , wherein X − is selected from the group consisting of PF 6 − , AlCl 4 − , ClO 4 − , BF 4 − , [B[3,5-(CF 3 ) 2 C 6 H 3 ] 4 ] − , B(C 6 F 5 ) 4 − and Al(OC(CF 3 ) 3 ) 4 − . 5. The process according to claim 4 , wherein X − is PF 6 − . 6. The process according to claim 1 , wherein said solvent is selected from the group consisting of toluene, THF (tetrahydrofuran), MTBE (methyl tertiary-butyl ether), water, ethanol, 2-propanol, NMP (N-Methyl-2-pyrrolidone), DMF (dimethylformamide), MIBK (methylisobutyl ketone), TEA (triethyl amine), DIPEA (N,N-diisopropylethylamine), DCM (dichloromethane), ethylacetate, isopropylacetate and combinations of these. 7. The process according to claim 1 , wherein R″ represents H. 8. The process according to claim 1 , wherein said de-complexation step comprises photolysis. 9. The process according to claim 1 , wherein 1 equivalent of a compound of formula I is mixed with a compound of formula II (1-5 equivalents) and a compound of formula III (1-5 equivalents) in a solvent together with a base (more than 0.5 equivalent) to obtain a compound of formula IV followed by de-complexation to obtain 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. 10. The process according to claim 1 , wherein 1 equivalent of a compound of compound of formula I is mixed with a base (between 0.5 and 20 equivalents), piperazine (1-5 equivalents) and 2,4-dimethyl thiophenol (1-5 equivalents) in a solvent to obtain a compound of formula IV, followed by de-complexation to obtain 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. 11. The process according to claim 1 , wherein 1 equivalent of η 6 -1,2-dichlorobenzene-η 5 -cyclopentadienyliron(II) hexafluorophosphate is mixed with 1-5 equivalent base, 1-3 equivalents 2,4-dimethylthiophenol and 1-3 equivalents piperazine in a solvent at 10° C-50° C. to obtain the compound of the formula followed by de-complexation to obtain 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. 12. The process according to claim 1 , wherein the obtained 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine is reacted with a suitable acid to obtain the equivalent pharmaceutically acceptable salt.
with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings · CPC title
Iron compounds · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.